CRISPR Therapeutics AG — Director's Dealing 2020

Dec 2, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: CRISPR Therapeutics AG (CRSP)
CIK: 0001674416
Period of Report: 2020-11-30

Reporting Person: Novak Rodger (Director, President)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-11-30	Common Shares	M	50000	$14.00	Acquired	698007	Direct
2020-11-30	Common Shares	S	50000	$125.00	Disposed	648007	Direct
2020-11-30	Common Shares	M	50000	$14.43	Acquired	698007	Direct
2020-11-30	Common Shares	S	50000	$125.00	Disposed	648007	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-11-30	Stock Option (Right to Buy)	$14.00	M	50000	Disposed	2026-10-18	Common Shares (50000)	Direct
2020-11-30	Stock Option (Right to Buy)	$14.43	M	50000	Disposed	2027-06-15	Common Shares (50000)	Direct

Footnotes

F1: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2: This option was granted on October 18, 2016 with respect to 200,000 Common Shares and originally vested in 48 equal monthly installments beginning October 31, 2016. Pursuant to Dr. Novak's amended and restated employment agreement with the Company, subject to his continued employment, beginning November 30, 2018, the remaining unvested options from this grant vest in equal monthly installments at the rate of 50% of the amounts originally scheduled to vest on any one vesting date, and the original vesting schedule was extended to reflect the amended schedule.

F3: This option was granted on June 15, 2017 with respect to 270,000 Common Shares and originally vested in 48 equal monthly installments commencing upon the grant date. Pursuant to Dr. Novak's amended and restated employment agreement with the Company, subject to his continued employment, beginning November 30, 2018, the remaining unvested options from this grant vest in equal monthly installments at the rate of 50% of the amounts originally scheduled to vest on any one vesting date, and the original vesting schedule was extended to reflect the amended schedule.